or Try an Advanced Search...

    Transplant Rejection Stocks List

    Symbol Grade Name % Change
    BMY B Bristol-Myers Squibb Company 0.60
    ALKS C Alkermes plc -0.75
    CDNA D CareDx, Inc. 0.94
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
    Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine

    Related ETFs - A few ETFs which own one or more of the above listed Transplant Rejection stocks.

    Symbol Grade Name Weight
    MEDX F Horizon Kinetics Medical ETF 10.14
    FTXH D First Trust Nasdaq Pharmaceuticals ETF 9.95
    PPH D Market Vectors Pharmaceutical ETF 5.89
    MVAL B SHL Telemedicine Ltd VanEck Morningstar Wide Moat Value ETF 5.37
    PSIL C AdvisorShares Psychedelics ETF 5.34
    View all Transplant Rejection ETFs...
    Compare ETFs
    Compare FTXH to PPH Compare MEDX to FTXH Compare MEDX to PSIL

        Transplant Rejection Stocks Recent News

        Date Stock Title
        Nov 21 BMY Major companies that are also popular short-selling stocks
        Nov 21 ALKS Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock?
        Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
        Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
        Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
        Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
        Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
        Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
        Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
        Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
        Nov 17 BMY Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
        Nov 15 BMY Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
        Nov 15 BMY Bristol Myers gets positive EMA opinion for repotrectinib
        Nov 15 CDNA After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
        Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
        Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major
        Related Stock Lists: Biopharmaceutical Depressive Disorder Diabetes Hypertension Organic Chemistry Schizophrenia Alcohol Angina Atrial Fibrillation Atypical Antipsychotics Biopharmaceutical Products Blood Test Cachexia Cancer Treatment Chemotherapy Cholesterol Chronic Myeloid Leukemia Clinic Clinical Medicine Cocaine
        Transplant Rejection

        Transplant rejection occurs when transplanted tissue is rejected by the recipient's immune system, which destroys the transplanted tissue. Transplant rejection can be lessened by determining the molecular similitude between donor and recipient and by use of immunosuppressant drugs after transplant.

        More about Transplant Rejection
        Browse All Tags